Selected publications
-
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
AIDS.
2018
Academic Article
GET IT
Times cited: 6 -
Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).
Clinical Lymphoma, Myeloma and Leukemia.
2018
Academic Article
GET IT
Times cited: 2 -
Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034.
Leukemia and Lymphoma.
2017
Academic Article
GET IT
Times cited: 2 -
Modernizing clinical trial eligibility criteria: Recommendations of the American society of clinical oncology-friends of cancer research HIV working group.
Journal of Clinical Oncology.
2017
Academic Article
GET IT
Times cited: 26 -
Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.
Journal of Clinical Pharmacology.
2016
Academic Article
GET IT
Times cited: 2 -
Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.
Cancer Medicine.
2014
Academic Article
GET IT
Times cited: 15 -
Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS malignancy consortium protocol 042.
Journal of Clinical Oncology.
2014
Academic Article
GET IT
Times cited: 46 -
Phase i pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
Investigational New Drugs.
2013
Academic Article
GET IT
Times cited: 15 -
Repurposing itraconazole as a treatment for advanced prostate cancer: A noncomparative randomized phase ii trial in men with metastatic castration-resistant prostate cancer.
Oncologist.
2013
Academic Article
GET IT
Times cited: 82 -
Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer.
Investigational New Drugs.
2012
Academic Article
GET IT
Times cited: 67 -
A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to smoothened antagonists.
Molecular Cancer Therapeutics.
2012
Academic Article
GET IT
Times cited: 56 -
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Cancer Discovery.
2011
Academic Article
GET IT
Times cited: 399 -
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
Investigational New Drugs.
2011
Academic Article
GET IT
Times cited: 8 -
Phase i trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
Clinical Colorectal Cancer.
2010
Academic Article
GET IT
Times cited: 16 -
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.
Translational Oncology.
2010
Academic Article
GET IT
Times cited: 13 -
Phase I study of ON 01910.Na, a novel modulator of the polo-like kinase 1 pathway, in adult patients with solid tumors.
Journal of Clinical Oncology.
2008
Academic Article
GET IT
Times cited: 87 -
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.
Journal of Clinical Oncology.
2008
Academic Article
GET IT
Times cited: 51 -
Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry.
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences.
2008
Academic Article
GET IT
Times cited: 3 -
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Cancer Chemotherapy and Pharmacology.
2008
Academic Article
GET IT
Times cited: 33 -
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma.
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences.
2007
Academic Article
GET IT
Times cited: 9 -
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences.
2007
Academic Article
GET IT
Times cited: 42 -
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent.
Clinical Cancer Research.
2005
Academic Article
GET IT
Times cited: 8 -
Synthesis and antitumor evaluation of benzoylphenylurea analogs.
Bioorganic and Medicinal Chemistry Letters.
2004
Academic Article
GET IT
Times cited: 23 -
Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry.
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences.
2003
Academic Article
GET IT
Times cited: 55 -
Development of matrix metalloproteinase inhibitors in cancer therapy.
Hematology/Oncology Clinics of North America.
2002
Review
GET IT
Times cited: 20